First-in-Class IL-4Rα/ST2 Bispecific Antibody AK139 Advances to Clinical Development for Inflammatory Diseases
核心洞察
Akeso (搜索)'s AK139, the world's first IL-4Rα (搜索)/ST2 (搜索) bispecific antibody, receives IND acceptance from China's NMPA for respiratory and skin diseases.
The novel dual-targeting mechanism simultaneously blocks IL-4/IL-13 and IL-33 (搜索)/ST2 (搜索) inflammatory pathways, showing superior efficacy compared to single-target therapies in preclinical studies.
Preclinical data demonstrates AK139's strong dual-specific binding activity, promising pharmacological effects, and favorable safety profile, positioning it as a potential breakthrough therapy.
Akeso (搜索), Inc. has achieved a significant milestone with the China National Medical Products Administration (NMPA) accepting the Investigational New Drug (IND) application for AK139, marking a pioneering advancement in inflammatory disease treatment. This first-in-class bispecific antibody uniquely targets both IL-4Rα (搜索) and ST2 (搜索), representing Akeso's initial venture into non-oncology bispecific antibodies.
Innovative Dual-Targeting Mechanism
AK139's breakthrough design simultaneously inhibits two critical inflammatory pathways: the IL-4/IL-13 axis through IL-4Rα (搜索) binding and the IL-33 (搜索)/ST2 (搜索)-mediated inflammation cascade. This dual-targeting approach addresses the complex inflammatory processes underlying various respiratory and dermatological conditions more comprehensively than existing single-target therapies.
The antibody's mechanism of action focuses on the IL-4Rα (搜索) pathway, which mediates T-helper 2 (Th2) cell responses through IL-4 and IL-13 signaling, while simultaneously blocking the IL-33 (搜索)/ST2 (搜索) pathway, which acts as a key inflammatory alarm signal in multiple biological systems.
Compelling Preclinical Evidence
Preclinical studies have demonstrated AK139's exceptional potential, with data showing:
- Superior efficacy in inhibiting inflammatory cytokine release compared to single-target antibodies
- Significant reduction in inflammatory cell tissue infiltration
- Strong dual-specific antigen-binding activity
- Favorable safety profile in toxicology studies
Clinical Development Prospects
As Akeso (搜索)'s seventh bispecific antibody to enter clinical development, AK139 represents a significant therapeutic advancement for patients with inadequate responses to current treatments. The drug shows particular promise for:
- Respiratory diseases including asthma and COPD
- Various dermatological conditions
- Other inflammatory disorders where IL-4/IL-13 and IL-33/ST2 pathways play crucial roles
The development of AK139 marks the beginning of a "dual-target era" in inflammatory disease treatment, potentially offering enhanced therapeutic options for patients who have not achieved optimal results with existing therapies.